These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25882710)

  • 1. Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.
    Wu Y; Enting D; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2015 May; 15(5):509-23. PubMed ID: 25882710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
    Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
    Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
    Loriot Y; Rouprêt M
    Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
    Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
    Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.].
    Carballido JA; Rodríguez Monsalve M
    Arch Esp Urol; 2018 May; 71(4):358-375. PubMed ID: 29745925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
    Chung R; McKiernan J; Arpaia N; Marabelle A; Rouanne M
    Eur J Cancer; 2023 Jul; 187():58-64. PubMed ID: 37116288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BCG Immunotherapy, past, present and future.].
    Rodríguez Faba Ó; Huguet Pérez J; Pisano F; Parada R; Palou J; Breda A
    Arch Esp Urol; 2020 Dec; 73(10):918-928. PubMed ID: 33269710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune therapies in non-muscle invasive bladder cancer.
    Ho PL; Williams SB; Kamat AM
    Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
    Kramer MW; Gakis G
    Urologe A; 2020 Jul; 59(7):784-789. PubMed ID: 32468091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
    Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
    Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Response to Intravesical Therapy.
    Li R; Kamat AM
    Urol Clin North Am; 2020 Feb; 47(1):23-33. PubMed ID: 31757297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.